without blasts in peripheral blood smear or cytopenia. 5 Further diagnostic investigations to exclude different types of hematologic malignancy are important before attributing peripheral blood eosinophilia to HES. 6 Herein we describe the case of a 10-year-old girl with acute B-cell lymphoblastic leukemia with myeloid antigen expression, in whom cytokine production in the lymphoblasts was investigated.
Case report
A 10-year-old girl developed pruritic, erythematous rash on her extremities, 6 months prior to presentation. One month prior to presentation, she had persistent skin rash and headache with an absolute eosinophil count of 8.93 ¥ 10 9 /L. She was then admitted to the National Defense Medical College hospital because of arthralgia in both wrists, swelling of right shoulder, and shortness of breath with exertion. Her past and family history was unremarkable. On admission her vital signs were within normal limits, with normal cardiopulmonary examination. On complete blood count the white blood cells (WBC) were 12.6 ¥ 10 9 /L, hemoglobin was 12.0 g/dL, and the platelets were 177 ¥ 10 9 /L with differential of neutrophilic bands (35%), neutrophilic segmentals (9%), lymphocytes (15%), and eosinophils (39%). There were no blasts on the peripheral blood smear. Eosinophils were hyperlobulated with decreased cytoplasmic granules (Fig. 1a) .
We investigated the etiology of eosinophilia and found elevated C-reactive protein of 3.5 mg/dL and erythrocyte sedimentation rate of 50 mm/h. Soluble interleukin-2 (IL-2) receptor was elevated at 4450 U/mL. Ova and parasite study of stool was negative. Chest radiography and computed tomography of the chest showed diffuse infiltrates in both lungs. The pulmonary function test showed a restrictive pattern. Echocardiography showed good biventricular function. We suspected HES, because the patient had multiple organ involvement with significant eosinophilia.
Bone marrow aspiration was performed to exclude hematologic malignancy and indicated hypercellular marrow with lymphoblasts 90% and eosinophils 2%. Lymphoblasts were L1 in the French-American-British classification and were negative on myeloperoxidase and periodic acid-Schiff stain (Fig. 1b) . Cytoplasmic granules of lymphoblasts were positive for anaphthyl-butyrate esterase without NaF inhibition (Fig. 1c) . Immunophenotyping on bone marrow CD45 dim cells showed lymphoblastic B-lineage cells expressing CD10, CD19, CD20, CD22, CD34, CD38, and the myeloid antigen CD33; this confirmed the diagnosis of acute precursor B-cell lymphoblastic leukemia. Cytogenetic analysis indicated normal karyotype 46,XX. Cerebrospinal fluid was negative for leukemia (1 WBC, 0 red blood cells, no blasts). The patient was enrolled in the Children's Cancer and Leukemia Study Group protocol ALL2004 (high-risk arm). Induction chemotherapy was initiated with adriamycin, vincristine, prednisone, and l-asparginase. Her symptoms, pulmonary infiltrates, and eosinophilia resolved quickly with induction chemotherapy, and the patient has remained in complete remission for 4 years since the onset of the disease.
We measured levels of IL-3, IL-5, and granulocyte macrophage-colony-stimulating factor (GM-CSF) in serum, using an ELISA kit (IL-3, GM-CSF: R&D Systems, Minneapolis, MN, USA; IL-5: Immunotech, Marseille, France). IL-3 and IL-5 in serum were elevated on admission, and normalized after induction therapy (Table 1) . We assayed the expression of Fip1-like1-platelet-derived growth factor receptor alpha (FIP1L1-PDGFRA) mRNA on reverse transcriptase-polymerase chain reaction (RT-PCR) using the lymphoblasts in bone marrow, as previously described. 7 RT-PCR of FIP1L1-PDFGRA mRNA was not detected in this case.
Discussion
Acute lymphoblastic leukemia with eosinophilia occurs rarely and 52 cases of ALLEo have been reported in 44 studies. 7, 8 A review of 38 cases of ALLEo reported male predominance (76%), a median age of 14 years, and a median absolute eosinophil count at presentation of 10.78 ¥ 10 9 /L as well as clinical presentation such as splenomegaly (60%), skin rash (54%), cough or dyspnea (43%), pneumonia or pulmonary infiltrates (51%), chest pain (20%), and adenopathy (46%). 2 Skin findings reported in 14 cases of ALLEo are diverse, including rash, purpura, ecchymosis, and one report of erythroderma. 3 Eosinophilia may antedate the development of ALL by several months to 2 years, and patients may present features of HES during this period. 9 Eosinophilia resolves with remission and usually returns with a relapse of the disease. 10 The majority of cases of ALLEo are of the B-cell type, and a few cases have been described of T-cell ALLEo; B-cell ALLEo with myeloid antigen expression; and biphenotypic (B-cell/T-cell) ALLEo.
1,5,10 Granular ALL confers a poor prognosis on children with ALL of the B-cell precursor phenotype, 11 and two cases of granular ALLEo have been described. 5, 12 Cytogenetic abnormalities have been detected in approximately half (30/52) of the patients with ALLEo. 4 The most common abnormality has been t(5;14)(q31;q32). This entity is now included as "B-lymphoblastic leukemia/lymphoma with t(5;14); IL-3-IGH" in the new World Health Organization classification of lymphoid neoplasms published in 2008. The present case was a rare form of B-cell ALLEo with granular lymphoblasts, myeloid antigen expression, and normal cytogenetic testing. The present patient has remained in remission for 4 years, and her symptoms, pulmonary infiltrates, and eosinophilia responded quickly to induction chemotherapy.
Eosinophilia is considered to be reactive in ALLEo and results from cytokine production by leukemic blasts (because chromosomal abnormality is usually found only in leukemic blasts); and eosinophils have normal karyotypes in 90% of cases. 4 In ALLEo with t(5;14)(q31:q32), eosinophilia is secondary to overproduction of IL-3 by the blasts due to activation of the IL-3 gene on chromosome 5 after its translocation, adjacent to the immunoglobulin heavy chain gene on chromosome 14. 8 In the present patient, the level of IL-3 and IL-5 in the serum was significantly elevated on admission and normalized with treatment. IL-3 and IL-5 were likely to be produced by the lymphoblasts. The present finding further supports the assumption that eosinophilia arises due to cytokine production by leukemic blasts in patients with ALLEo. We cannot, however, exclude the possibility that activated leukocytes including eosinophils produce a large amount of cytokines. In addition, chemotherapy reduces normal hematopoietic cells as well as leukemic cells.
The FIP1L1-PDGFRA fusion has been described in patients with chronic eosinophilic leukemia, which can present as idiopathic HES. Recent report showed that the presence of the FIP1L1-PDGFRA fusion gene was detected in five patients with acute myeloid leukemia and associated eosinophilia. 13 In these cases, FIP1L1-PDGFRA-positive cells were seen in >90% of all marrow cells, clearly indicating that blast cells were indeed FIP1L1-PDGFRA positive. The presence of FIP1L1-PDGFRA was confirmed in all these cases by amplification and sequencing of the RNA fusion sequences on RT-PCR and of the genomic DNA fusion sequences on long-template-PCR and bubble-PCR. In the present case, we investigated the presence of FIP1L1-PDGFRA mRNA in lymphoblasts in bone marrow, because this fusion gene was reported in the blasts of acute myeloid leukemia.
In conclusion, we describe a rare form of granular B-cell ALLEo with myeloid antigen expression. Eosinophilia disappeared along with the normalization of IL-3 and IL-5 in the serum on chemotherapy; it further supports the reactive nature of eosinophilia in ALLEo. FIP1L1-PDGFRA was negative, and clinical response to chemotherapy was excellent with achievement of complete remission for 4 years. Hematologic malignancy should be considered in every patient with hyper-eosinophilia, before attributing it to HES. Granulocyte macrophage-colony-stimulating factor.
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